Apollo Biowellness, Inc., Outlook for the Remainder of 2025

Rhea-AI Summary

Apollo Biowellness (OTC Pink: KOAN) has announced several strategic initiatives for 2025-2026. The company has secured an exclusive distribution agreement with Revive Regenerative for its Evo Bio Brand in North America, targeting Med Spas, Injectors, and Plastic Surgeons. The company is also exploring distribution partnerships in Europe, Asia, and the Middle East.

Key upcoming developments include the launch of a shelf-stabilized biologic cosmetic brand in Q3 2025 for retail and direct-to-consumer channels, and a partnership with an Israeli biotech firm to develop placental-based biologics for pets launching in Q1 2026. The Evo Bio division is currently operating at a $2.2M annual run rate, with expectations for significant growth through 2025-2026.

Positive

• Current Evo Bio division operating at $2.2M annual run rate
• Exclusive North American distribution agreement secured with Revive Regenerative
• New shelf-stable cosmetic product launch planned for Q3 2025
• Strategic shift to R&D and manufacturing focus while leveraging established distribution channels
• Geographic expansion planned across Europe, Asia, and Middle East markets

Negative

• New business model implementation may take time to show results
• Pet biologics product launch delayed until Q1 2026
• Heavy reliance on distribution partners for sales and marketing

North Bergen, New Jersey--(Newsfile Corp. - July 9, 2025) - Apollo Biowellness, Inc. (OTC Pink: KOAN) (the "Company"), as previously announced, the Company has officially entered into an exclusive distribution and marketing agreement for North America, only, with Revive Regenerative, Inc., for its Evo Bio Brand for Med Spas, Injectors, Plastic Surgeon, etc. In addition, the Company is in discussions with various other laser and device manufacturers in Europe, Asia and the Middle East for additional distribution of your biologic products in those various regions.

Evolutionary Biologics Ad Campaign

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10533/258139_53768fd164446b62_001full.jpg

The Company has plans to launch a consumer shelf stabilized biologic cosmetic brand before the end of the third quarter of 2025. It will be a shelf stabilized biologics cosmetic where no refrigeration is needed as our current Evo Bio Product requires, where we will be selling the product into retail or direct to consumer and e-commerce platforms, including TV shopping directly to consumers.

Lastly, the Company is in discussions with a substantial Israeli based biologic bio-tech manufacturer, to create the first placental based biologic focused on pets, dealing with various health issues surrounding dogs and cats, focused on joint issues arthritic issues and post-surgery issues. This new product will be launched into production and sales in the first quarter of 2026.

This new model and structure for the Company refocusing on R&D, production and manufacturing and wholesale distribution, will allow us to focus our attention on the creation of and development of the products, manufacturing of the products, maintaining IP and SOP's, by allowing sales and marketing to be handled by large companies with significant distribution capabilities.

The Company's currently operating division, Evo Bio, is currently operating at a $2.2M run rate for the year, and with the new model of distribution and the expansion of new markets we are expecting significant growth to our top line and bottom-line, starting with the remainder of 2025, but expecting significant growth in 2026.

James W. Zimbler, President stated, "In furthering the new business model of the Company, of becoming an R&D, manufacturing production biologics company, selling through larger distribution channels allows us to focus on our core competency of development and procurement and brands, rather than focusing on managing the sales process, and allows us a larger expansion and scale"

You can follow and contact the Company on X at @ApolloBioKOAN.

About Apollo Biowellness, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.

Before using any of our products, you should always consult with your veterinarian and/or family doctor.

Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.

Corporate Contact
James W. Zimbler
President/CEO/Director
info@evolutionarybiologics.com
https://evobiologics.com/
631-806-1420

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258139

FAQ

What is Apollo Biowellness's (KOAN) current annual revenue run rate?

Apollo Biowellness's Evo Bio division is currently operating at a $2.2M annual run rate for the year.

When will KOAN launch its new shelf-stabilized biologic cosmetic brand?

Apollo Biowellness plans to launch its shelf-stabilized biologic cosmetic brand before the end of the third quarter of 2025.

What is Apollo Biowellness's new distribution agreement for North America?

The company has entered an exclusive distribution and marketing agreement with Revive Regenerative for its Evo Bio Brand, targeting Med Spas, Injectors, and Plastic Surgeons in North America.

What new pet-focused product is KOAN developing?

Apollo Biowellness is developing the first placental-based biologic for pets in partnership with an Israeli biotech manufacturer, focusing on joint issues, arthritic issues, and post-surgery issues in dogs and cats, launching in Q1 2026.

What is Apollo Biowellness's new business strategy?

The company is refocusing on R&D, production, and manufacturing while partnering with large distribution companies to handle sales and marketing, allowing them to focus on core competencies in development and procurement.